比较经支气管超声引导下不同取样技术对纵隔病变的诊断效能:一项网状Meta分析
该网状Meta分析纳入35项研究、3751例患者,比较EBUS-TBNA、EBUS-IFB、EBUS-TBNB和EBUS-TMC对纵隔病变的诊断率。结果显示EBUS-TMC和EBUS-IFB可能优于EBUS-TBNA,但所有95%预测区间均跨越无效线,证据确定性极低,结论仅为假说生成性。
要点
- EBUS-TMC和EBUS-IFB的诊断率可能优于EBUS-TBNA,但预测区间宽泛提示结果可重复性不确定。
- 在良性疾病、结节病和淋巴瘤中EBUS-TMC与EBUS-IFB获益更明显,肺癌中表现相似。
- EBUS-TMC报告的不良事件率较高,但多数为轻至中度。
核心结论
- 在特定疾病和有经验的中心,EBUS-TMC和EBUS-IFB可能较EBUS-TBNA提高诊断率,但证据确定性极低,应视为假说生成而非确定性证据。
研究设计与样本
- 随机效应网状Meta分析,同时采用贝叶斯和频率学框架,纳入35项研究共3751例患者。
主要发现
- EBUS-TMC较EBUS-TBNA的诊断率RR为1.27(95%CI 1.16-1.39;95%PrI 0.89-1.81)。
- EBUS-IFB较EBUS-TBNA的诊断率RR为1.21(95%CI 1.07-1.38;95%PrI 0.84-1.75)。
- EBUS-TBNB较EBUS-TBNA未见明确优势,RR为1.10(95%CI 0.98-1.23)。
- 所有95%预测区间均跨越1,提示未来场景下结果可重复性存在不确定性。
- SUCRA排序依次为EBUS-TMC、EBUS-IFB、EBUS-TBNB、EBUS-TBNA,但不应解读为 superiority 的确定性。
关键数值与推荐
- 亚组分析提示EBUS-TMC和EBUS-IFB在良性疾病、结节病和淋巴瘤中获益更大,肺癌中表现相似。
- 多数不良事件为轻至中度,但EBUS-TMC报告的不良事件率更高。
临床怎么用
- 临床选择取样技术时需结合疾病类型和中心经验,EBUS-TMC和EBUS-IFB可考虑用于良性疾病、结节病或淋巴瘤等特定情况。
- 因证据确定性极低且预测区间宽泛,不应将SUCRA排序视为技术优劣的确定性依据。
局限性
- 证据确定性极低,95%预测区间均跨越无效线,结果可重复性不确定。
- SUCRA排序为探索性,不能解释为优越性的确定性证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comparative evidence on the diagnostic yield of endobronchial ultrasound (EBUS)-guided sampling techniques for mediastinal lesions remains limited. We conducted a network meta-analysis (NMA) to evaluate EBUS-guided transbronchial needle aspiration (EBUS-TBNA), intranodal forceps biopsy (EBUS-IFB), transbronchial needle core biopsy (EBUS-TBNB) and transbronchial mediastinal cryobiopsy (EBUS-TMC). METHODS: Random-effects NMA was performed within Bayesian and frequentist frameworks. Frequentist estimates were reported as risk ratios (RRs) with 95% CIs and, where applicable, 95% predictive intervals (PrIs). Bayesian ranking was assessed using surface under the cumulative ranking curve (SUCRA) values. RESULTS: 35 studies involving 3751 patients were included. EBUS-TMC (RR 1.27, 95% CI 1.16 to 1.39; 95% PrI 0.89-1.81) and EBUS-IFB (RR 1.21, 95% CI 1.07 to 1.38; 95% PrI 0.84-1.75) may provide higher diagnostic yield than EBUS-TBNA, whereas EBUS-TBNB did not show a clear advantage (RR 1.10, 95% CI 0.98 to 1.23). However, all 95% PrIs crossed unity, suggesting uncertainty about reproducibility in future settings. SUCRA rankings favoured EBUS-TMC followed by EBUS-IFB, EBUS-TBNB and EBUS-TBNA but should not be interpreted as certainty of superiority. Subgroup analyses suggested greater benefits of EBUS-TMC and EBUS-IFB in benign diseases, sarcoidosis and lymphoma but similar performance in lung cancer. Most adverse events were mild to moderate, although EBUS-TMC had a higher reported adverse-event rate. CONCLUSION: EBUS-TMC and EBUS-IFB may improve diagnostic yield over EBUS-TBNA in selected diseases and experienced centres. Given the very low certainty of evidence, wide PrIs and exploratory SUCRA rankings, these findings should be viewed as hypothesis-generating rather than definitive evidence. PROSPERO REGISTRATION NUMBER: CRD420251236286.
引用
- Luo Y, Li SP. Comparative performance of endobronchial ultrasound-guided sampling techniques in patients with mediastinal lesions: a network meta-analysis. Thorax. 2026. PMID: 42379887. doi:10.1136/thorax-2025-224563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。